Bio-Techne ( (TECH) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Bio-Techne shares are sliding after Citi cut its rating on the stock from Buy to Neutral, arguing that the shares have become too expensive given mounting valuation risks and a tougher macro backdrop for life-science tools. The downgrade landed just as Fed minutes signaled officials are still open to more rate hikes if inflation stays sticky, adding pressure on the entire growth-sensitive sector and turning Bio-Techne into one of today’s notable underperformers.
Analysts did not flag any change to Bio-Techne’s fundamental story, but the combination of a more cautious stance on the stock and sector-wide jitters has weighed heavily on sentiment. With investors reassessing how much they are willing to pay for future growth in a higher-for-longer rate environment, the stock is bearing the brunt of this reassessment today.
Looking beyond today’s selloff, Bio-Techne’s business model still has attractions for long-term investors because a large portion of its sales comes from recurring purchases of reagents and consumables tied to its specialized platforms. That kind of repeat business can help smooth revenue and deepen customer relationships over time, especially as tools like RNAscope and ProteinSimple become more embedded in research and clinical workflows.
The flip side is that Bio-Techne’s profits and cash generation have been jumpy, which can make its future performance harder to forecast and may keep some investors on the sidelines. On top of that, the planned Merck acquisition is not yet a done deal, so any delay or failure to close could extend uncertainty around strategy and limit how quickly the company can capitalize on the scale and distribution benefits that investors are currently counting on.
More about Bio-Techne
YTD Price Performance: 23.69%
Average Trading Volume: 3,122,405
Technical Sentiment Signal: Buy
Current Market Cap: $11.38B
For further insights into TECH stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.


